Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Galectin Therapeutics Company Profile (NASDAQ:GALT)

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $16.00 (492.59% upside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetActions
3/12/2015MLV & Co.Reiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2015MLV & Co.Set Price TargetBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/1/2014AegisDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2014BMO Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2014MLV & Co.Lower Price TargetBuy$27.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2014AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2014MLV & Co.Boost Price TargetBuy$20.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2014AegisBoost Price TargetBuy$16.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2014AegisBoost Price TargetBuy$10.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2013MLV & Co.Initiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2013Ascendiant Capital MarketsInitiated CoverageBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2013AegisBoost Price TargetBuy$7.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/27/2013 forward)